Amolimogene bepiplasmid

Drug Profile

Amolimogene bepiplasmid

Alternative Names: E7101; HPV-E6-E7-plasmid; ZYC 101; ZYC00101; ZYC101a

Latest Information Update: 22 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MGI Pharma Biologics
  • Developer Eisai Co Ltd; MGI Pharma Biologics
  • Class Cancer vaccines; DNA; Gene therapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cervical dysplasia
  • Discontinued Anal dysplasia

Most Recent Events

  • 22 Sep 2017 No recent reports on development identified- Phase-II/III for Cervical dysplasia in USA (IM)
  • 06 Jul 2011 MGI PHARMA completes a phase II/III trial in Cervical dysplasia in US (NCT00264732)
  • 11 Jul 2008 Amolimogene is still in phase II/III trials for Cervical dysplasia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top